Video
Video
Daniel Tennenbaum, MDPhenotypic Precision Medicine in Advanced Prostate Cancer | November 15, 2022
Andrew Armstrong, MD ScM FACP, is interviewed by Daniel Tennenbaum, MD on new research in phenotypic precision medicine.
Read More
The UromigosUromigos Live and Unplugged | November 9, 2022
Cancer patient Michael Whitley explains how The Uromigos help him understand new prostate cancer treatments and research.
The UromigosUromigos Live and Unplugged | November 9, 2022
Matthew Tucker, MD from Grandview Cancer Center talks about why he enjoys The Uromigos and what his favorite episodes are.
The UromigosUromigos Live and Unplugged | November 9, 2022
Chandler Park, MD from University of Louisville Hospital talks about why he recommends The Uromigos podcast.
The UromigosUromigos Live and Unplugged | November 8, 2022
Petros Grivas, MD, PhD, Director of UW Medicine's GU Cancers Program, talks about the efficacy of sacituzumab govitecan.
The UromigosUromigos Live and Unplugged | November 8, 2022
Shilpa Gupta, MD discusses maintenance therapy for bladder cancer, including the current standard of care and ongoing trials.
The UromigosUromigos Live and Unplugged | November 8, 2022
Thomas Powles, MBBS, MRCP, MD gives an overview of highlights from The Uromigos: Live & Unplugged bladder cancer session.
The UromigosUromigos Live and Unplugged | November 8, 2022
Matthew Galsky, MD gives insight on adjuvant nivolumab trials, including use in unselected patients and overall survival.
The UromigosUromigos Live and Unplugged | November 8, 2022
Kala Sridhar talks about bladder-sparing treatments for urothelial carcinoma and how patient populations are shifting.
The UromigosUromigos Live and Unplugged | November 8, 2022
Jonathan Rosenberg, MD talks about the development of enfortumab vedotin, including monotherapy info and combination data.
The UromigosUromigos Live and Unplugged | November 8, 2022
Christopher Sweeney talks about prostate cancer trials investigating the use of ADT + docetaxel or cabazitaxel.
The UromigosUromigos Live and Unplugged | November 8, 2022
Christopher Sweeney, MBBS, gives us his insight on the future of prostate cancer care and research in the year 2027.
The UromigosUromigos Live and Unplugged | November 4, 2022
Nick James, MBBS, PhD, FRCP, FRCR, discusses his outlook on the future of prostate cancer treatment in the year 2027.
The UromigosUromigos Live and Unplugged | November 4, 2022
Daniel George, MD, Duke University School of Medicine, gives us insight on what to expect from the future of mHSPC treatment.
The UromigosUromigos Live and Unplugged | November 4, 2022
Neeraj Agarwal, MD, Professor of Medicine, gives his outlook on the future of cancer care and treatment for mHSPC in 2027.
The UromigosUromigos Live and Unplugged | November 4, 2022
Sumanta Pal, MD, FASCO, from City of Hope talks about new drugs and the ongoing TiNivo-2 trial for renal cell carcinoma.
The UromigosUromigos Live and Unplugged | November 4, 2022
David McDermott, MD talks about monotherapy and combination therapy for RCC and future advances in RCC treatment.
The UromigosUromigos Live and Unplugged | November 4, 2022
Rana McKay, MD, GU Medical Oncologist from UCSD, gives her outlook on the future of prostate cancer care in the year 2025.
The UromigosUromigos Live and Unplugged | November 4, 2022
Michael Morris, MD, of Memorial Sloan Kettering Cancer Center gives his predictions for the future of mHSPC treatment.
Daniel Tennenbaum, MDPhenotypic Precision Medicine in Advanced Prostate Cancer | October 27, 2022
Andrew Armstrong, MD ScM FACP, is interviewed by Daniel Tennenbaum, MD on the role of pain in prostate cancer.
Advertisement
Advertisement